Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 1,163
- 主要终点
- Overall survival of mCRPC patients
研究概览
简要总结
The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs associated with that diagnosis and subsequent treatments.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 55 Years 至 88 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •First diagnosis for bone metastases for members diagnosed with prostate cancer found in the claims data during the identification period
- •Members age ≥ 55 to 89 years at index
- •Medicare members with medical and pharmacy coverage; and
- •Continuously enrolled during the pre- and post-index periods.
排除标准
- •Member with diagnosis of any other cancer (excluding melanoma (ICD-9 172.x) and other metastases (ICD-9 198.x)) before the index date; and
- •Members age ≥ 89 years of age at index date
研究组 & 干预措施
Cohort 1 / Treatment patterns
Patients with castrated resistant prostate cancer and bone metastases
干预措施: Radium-223 dichloride (Xofigo, BAY88-8223) (Drug)
结局指标
主要结局
Overall survival of mCRPC patients
时间窗: Up to 24 months
mCRPC: Metastatic castrate-resistant prostate cancer
Number of skeletal related events (SREs) of the mCRPC patients
时间窗: Up to 30 months
Duration for each treatment identified
时间窗: Up to 30 months
Clinical and demographic characteristics of the mCRPC patients
时间窗: Up to 12 months
Gender, age, geographical region and race/ethnicity, Key comorbidities will also be documented using the Deyo-Charlson Comorbidity Index (DCCI); laboratory results for Prostate-Specific Antigen (PSA) and alkaline phosphatase (ALP) testing using laboratory claims; Rx utilization including opioid use
Type of skeletal related events (SREs) of the mCRPC patients
时间窗: Up to 30 months
Number of patients with mCRPC with bone metastases
时间窗: Up to 24 months
Type of treatments associated with mCRPC
时间窗: Up to 24 months
Treatments could include chemotherapy or bone radiation
Distribution of providers by treatment
时间窗: Up to 30 months
Distribution of treatments for mCRPC patients will be tracked by the type of provider (oncologist, versus urologist, versus radiation oncologist, etc)
Treatment patterns of mCRPC patients with bone metastases
时间窗: Up to 30 months
Progression of the disease of mCRPC patients
时间窗: Up to 12 months
次要结局
- All-cause healthcare resource utilization for mCRPC patients(Up to 30 months)
- mCRPC-specific healthcare costs for mCRPC patients(Up to 30 months)
- All-cause healthcare costs for mCRPC patients(Up to 30 months)
- mCRPC-specific healthcare resource utilization for mCRPC patients(Up to 30 months)